ArticleJournal of neuro-oncology2013
Expression of alarin in ependymoma and choroid plexus tumors.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications.Frontiers in endocrinology · 2022Review
- Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor.Frontiers in psychiatry · 2022Review
- Alarin in different human intestinal epithelial cell types.Histochemistry and cell biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alarin, a 25 amino acid splice variant of the galanin-like peptide, was originally discovered in gangliocytes of neuroblastic tumors and shown to be expressed in ganglioneuroblastoma and ganglioneuroma but not in undifferentiated neuroblastoma. Recently, in vivo studies have elucidated the physiological functions of alarin in the central nervous system (CNS). Alarin was shown to stimulate food intake, increase body weight, induce luteinizing hormone secretion and stimulate fos-expression in rats; the anatomical localization for these functions correlates well with the varied distribution of the alarin peptide in the brain. Because alarin was originally detected in neuroblastic tumors and is present in a wide range of nuclei in the CNS, we determined in the present study the expression of alarin in a variety of CNS tumors. Immunohistochemical analysis of 179 tumor samples resulted in different alarin-like immunoreactivity (alarin-LI) intensities, which were score-rated from 0 (no alarin stainin), 1 (low intensity), 2 (medium intensity) to 3 (high intensity). Immunohistochemical analyses revealed score 2 or 3 alarin-LI in all choroid plexus tumors (100 %, 7/7) and in the majority of ependymomas (90 %, 52/58), but only in a minority of astrocytomas (15 %, 5/33), meningiomas (14 %, 7/49) and tumors of the cranial nerves (7 %, 1/15). In oligodendrogliomas (0 %, 0/12) and oligoastrocytoma (0 %, 0/5) alarin-LI was not detectable. The high specificity (83 %) of alarin-LI suggests that it might be used as a diagnostic marker for ependymoma in differentiating them from other gliomas such as astrocytomas and oligodendrogliomas.
Indexed as
Identifiers
23761022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.